Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
We have reported that serum IL-6 level was related with the degree of anemia in monkey collagen-induced arthritis (CIA). In this study, we examined whether IL-6 blockade ameliorated an anemia in monkey CIA. CIA was induced by twice immunization of bovine type II collagen with adjuvant. When anemia became evident, anti-IL-6 receptor antibody, tocilizumab was intravenously injected once a week for 4 weeks. Controls received PBS in a same manner. Hematological and biochemical parameters were measured regularly and serum hepcidin-25 levels were measured by SELDI-TOF mass spectrometry. Moreover, hepcidin mRNA induction in Hep3B cells by serum from arthritic monkeys was examined by real-time PCR. Administration of tocilizumab rapidly decreased CRP levels and improved iron-deficient anemia within 1 week. Tocilizumab induced rapid but transient reduction in serum hepcidin-25. Hepcidin mRNA expression was more potently induced by serum from arthritic monkey and this was inhibited by the addition of tocilizumab. Blockade of IL-6 signaling rapidly improved anemia in monkey arthritis via the inhibition of IL-6-induced hepcidin production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tocilizumab administration also lowered hepcidin and improved anemia in rheumatoid arthritis patients (Isaacs et al., 2013; Song et al., 2013) and in a monkey arthritis model (Hashizume et al., 2010).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Hashizume et al., 2010
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“(2) IL-6 induces hepcidin production in liver cells [11].”
BackgroundPigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 1×
“In the study to examine the eVect of monkey serum, the cells were starved of FBS for 24 h because it is reported that FBS induces hepcidin mRNA expression [15].”
BackgroundHepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544 · cited 1×
“Hepcidin is a master regulator of iron homeostasis in humans and other mammals [5].”
BackgroundSmolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Severe iron deficiency anemia in transgenic mice expressing liver hepcidin
Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C., Grandchamp, B., Sirito, M., Sawadogo, M., Kahn, A., & Vaulont, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072632499 · Cited by 880
Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 788
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimi, M., Maid, R., Feldmann, M., et al. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181122 · Cited by 784
Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531
Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J. R., Antoni, C., Breedveld, F. C., Smolen, J. S., Eberl, G., deWoody, K., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1521 · Cited by 436
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Ganz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
Hepcidin and iron regulation, 10 years later
Ganz, T. (2011) · Blood · doi:10.1182/blood-2011-01-258467 · Cited by 962
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895
Self-citationHepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466
The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Hashizume, M., & Mihara, M. (2011) · Arthritis · doi:10.1155/2011/765624 · Cited by 238
Self-citationHepcidin in Human Iron Disorders: Diagnostic Implications
Kroot, J. J., Tjalsma, H., Fleming, R. E., & Swinkels, D. W. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2009.140053 · Cited by 246
Sun, C. C., Vaja, V., Babitt, J. L., & Lin, H. Y. (2012) · American Journal of Hematology · doi:10.1002/ajh.23110 · Cited by 185
The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders
Ganz, T., & Nemeth, E. (2011) · Hematology · doi:10.1182/asheducation-2011.1.538 · Cited by 172
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
“The efficacy of pharmaceutical hepcidin inhibition has already been demonstrated with an anti-hepcidin antibody in mice(10) and by other less specific approaches with an indirect effect on hepcidin expression.(11,12) NOX-H94 (sequence in the supplemental data; see the Blood Web site) is a structured mirror-image L-oli…”
BackgroundIron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
Hepcidin: A Promising Therapeutic Target for Iron Disorders A Systematic Review
Liu, J. L., Sun, B., Yin, H.-J., & Liu, S. (2016) · Medicine · doi:10.1097/md.0000000000003150 · Cited by 156
Pharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
Gangat, N., & Wolanskyj, A. P. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.006 · Cited by 134
Manipulation of the hepcidin pathway for therapeutic purposes
Fung, E., & Nemeth, E. (2013) · Haematologica · doi:10.3324/haematol.2013.084624 · Cited by 123
Hepcidin antagonists for potential treatments of disorders with hepcidin excess
Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., & Arosio, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00086 · Cited by 124
Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis
Wei, S., Sun, Y., Zong, S., & Xiang, Y. (2015) · Medical Science Monitor · doi:10.12659/msm.895116 · Cited by 140
Anemia of Chronic Diseases: Wider Diagnostics—Better Treatment?
Wiciński, M., Liczner, G., Cadelski, K., Kołnierzak, T., Nowaczewska, M., & Malinowski, B. (2020) · Nutrients · doi:10.3390/nu12061784 · Cited by 153
Katsarou, A., & Pantopoulos, K. (2018) · Pharmaceuticals · doi:10.3390/ph11040127 · Cited by 112
Iron and hepcidin: a story of recycling and balance
Camaschella, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.1 · Cited by 112
Hepcidin in human iron disorders: Therapeutic implications
Pietrangelo, A. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.004 · Cited by 116
van Eijk, L. T., John, A. S. E., Schwoebel, F., Summo, L., Vauléon, S., Zöllner, S., Laarakkers, C. M., Kox, M., van der Hoeven, J. G., Swinkels, D. W., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559484 · Cited by 110
Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4397 · Cited by 105
“Tocilizumab reduces hepcidin levels and improves anaemia in patients with Castleman’s disease [1] and in an animal model of arthritis [10].”
BackgroundMurawska, N., Fabisiak, A., & Fichna, J. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000648 · Cited by 105
Agarwal, A. K., & Yee, J. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.005 · Cited by 99
Masson, C. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.05.017 · Cited by 82
Zumbrennen‐Bullough, K. B., & Babitt, J. L. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft443 · Cited by 92
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Mihara, M., Ohsugi, Y., & Kishimoto (2011) · Open Access Rheumatology: Research and Reviews · doi:10.2147/oarrr.s17118 · Cited by 75
Self-citationHepcidin: Homeostasis and Diseases Related to Iron Metabolism
Reichert, C. O., da Cunha, J., Levy, D., Maselli, L. M. F., Bydlowski, S. P., & Spada, C. (2017) · Acta Haematologica · doi:10.1159/000471838 · Cited by 85
Bugelski, P. J., & Martin, P. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01811.x · Cited by 71
Interleukin-6 contributes to hepcidin mRNA increase in response to exercise
Banzet, S., Sanchez, H., Chapot, R., Bigard, X. A., Vaulont, S., & Koulmann, N. (2012) · Cytokine · doi:10.1016/j.cyto.2012.01.006 · Cited by 71
Hashizume, M., Tan, S., Takano, J., Ohsawa, K., Hasada, I., Hanasaki, A., Ito, I., Mihara, M., & Nishida, K. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.938325 · Cited by 69
Self-citationRobson-Ansley, P. J., Walshe, I. H., & Ward, D. G. (2010) · Cytokine · doi:10.1016/j.cyto.2010.10.001 · Cited by 70
Management of Anemia in Patients with Inflammatory Bowel Disease (IBD)
Patel, D., Trivedi, C. P., & Khan, N. H. (2018) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-018-0174-2 · Cited by 60
Iron deficiency anemia in IBD: an overlooked comorbidity
Shah, Y., Patel, D., & Khan, N. H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1900730 · Cited by 52
Diagnosis and treatment of anemia in patients with inflammatory bowel disease
Mücke, V. T., Mücke, M. M., Raine, T., & Bettenworth, D. (2016) · Annals of Gastroenterology · doi:10.20524/aog.2016.0083 · Cited by 50
Du, Y., Liu, X., Pan, R., Zhang, X., Si, X., Chen, M., Mengzhao, W. A. N. G., & Zhang, L. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13638 · Cited by 38
Sim, M., Dawson, B., Landers, G., Trinder, D., & Peeling, P. (2014) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2013-0067 · Cited by 36
Zeybek, B., Childress, A. M., Kilic, G. S., Phelps, J. Y., Pacheco, L. D., Carter, M. A., & Borahay, M. A. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000343 · Cited by 37
Immunotherapies in Rheumatologic Disorders
Miller, A. V., & Ranatunga, S. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.003 · Cited by 35
Wang, C., Fang, Z., Zhu, Z., Liu, J., & Chen, H. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.05.002 · Cited by 30
Burns, J. L., Miller, C. H., Fontaine‐Bisson, B., & Connor, K. L. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127684 · Cited by 29
Insights into the diagnosis and management of iron deficiency in inflammatory bowel disease
Bou‐Fakhredin, R., Halawi, R., Roumi, J. E., & Taher, A. T. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1355233 · Cited by 25
Arthritis, Muscle, Adipose Tissue, and Bone Diseases of Nonhuman Primates
Pritzker, K. P. H., & Kessler, M. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381366-4.00013-4 · Cited by 30
Therapeutic apheresis in autoimmune diseases
Bambauer, R., Bambauer, C., Latza, R., Schiel, & Burgard, D. (2013) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s34616 · Cited by 21
Role of Hepcidin in Iron Metabolism and Potential Clinical Applications
Grimes, C. N., Giori, L., & Fry, M. M. (2012) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2011.10.002 · Cited by 21
The role of heparin, heparanase and heparan sulfates in hepcidin regulation
Asperti, M., Denardo, A., Gryzik, M., Arosio, P., & Poli, M. (2019) · Vitamins and hormones · doi:10.1016/bs.vh.2019.01.008 · Cited by 18
Erythropoietic stimulating agents
Testa, U. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903499273 · Cited by 18
A tincture of hepcidin cures all: the potential for hepcidin therapeutics
Bartnikas, T. B., & Fleming, M. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci45043 · Cited by 16
Therapeutic Apheresis in Hematologic, Autoimmune and Dermatologic Diseases With Immunologic Origin
Bambauer, R., Latza, R., Burgard, D., & Schiel, R. (2016) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12474 · Cited by 16
Current Landscape of Hepcidin Therapeutics
Nai, A., Silvestri, L., Asperti, M., & Vinchi, F. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_26 · Cited by 15
Zhu, J., Fu, Q., Wang, S., Ren, L., Feng, W., Wei, S., Zhang, Z., Xu, Y. H., Ganz, T., & Liu, S. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c04260 · Cited by 14
How and why systemic inflammation worsens quality of life in patients with advanced cancer
McSorley, S. T., Dolan, R. D., Roxburgh, C. S. D., McMillan, D. C., & Horgan, P. G. (2017) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1331705 · Cited by 14
Elsheemy, M. S. A.-E., Hasanin, A. H., Mansour, A., Mehrez, S. I., & Abdelbary, M. S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108740 · Cited by 15
Tocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients
Guz, D., Gafter‐Gvili, A., Lev, N., Levin, G. S., & Lev, S. (2022) · Acta Haematologica · doi:10.1159/000522307 · Cited by 10
Tong, J., Tong, M., Kang, N., Liu, F., Zhang, K., Liang, W., Peng, S., Li, Z., Xue, T., Xiang, H., et al. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.4c07787 · Cited by 9
Park, K., Jin, H., Cho, Y., Kang, J.-H., Jung, H., Kang, J., Kim, J.-E., Yim, Y., Lee, J., Lee, K.-E., et al. (2016) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2016.23.1.37 · Cited by 7
Rodrigues, M. I. D. Q., Martins, J. O. D. L., Silva, P. G. D. B., Júnior, A. E. C. F., Verde, M. E. Q. L., Sousa, F. B., Mota, M. R. L., & Alves, A. P. N. N. (2020) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2020.08.012 · Cited by 7
Harada, M., Honma, Y., Shiba, E., Tomosugi, N., & Harada, R. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4329-24 · Cited by 5
Self-citationСаприна, Т. В., Zima, A. P., Мусина, Н. Н., Prokhorenko, T. S., Latypova, A. V., Shakhmanova, N. S., & Budeeva, S. V. (2019) · Diabetes Mellitus · doi:10.14341/dm9378 · Cited by 5
Wijekoon, S., SUNAGA, T., Wang, Y., MWALE, C., Kim, S., & Okumura, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265596 · Cited by 5
Suzuki, K., Akiyama, M., Saito, K., Shimanuki, K., & Kaneko, Y. (2025) · Rheumatology International · doi:10.1007/s00296-025-05880-w · Cited by 4
Reichert, C. O., da Cunha, J., Levy, D., Maselli, L. M. F., Bydlowski, S. P., & Spada, C. (2017) · InTech eBooks · doi:10.5772/intechopen.69507 · Cited by 5
Weiler, S., & Nairz, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627223 · Cited by 4
Słomka, A., Koba, M., Kulwas, A., & Żekanowska, E. (2011) · Current Pharmaceutical Analysis · doi:10.2174/157341211796353309 · Cited by 3
The role of hepcidin in iron metabolism
Adamska-Tomaszewska, D., & Więcek, S. (2025) · Pediatria Polska · doi:10.5114/polp.2025.154704 · Cited by 1
Anemia of Chronic Disease: Pathophysiology, Diagnosis and Management
Abbotts, K., & Sriskandarajah, P. (2026) · Hematology Reports · doi:10.3390/hematolrep18040048 · Cited by 2
L’anémie de la polyarthrite rhumatoïde
Masson, C. (2010) · Revue du Rhumatisme · doi:10.1016/s1169-8330(10)70005-3 · Cited by 1
Effect of exercise on inflammation, hepcidin regulation and iron metabolism
Sim, M. (2014) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 1
Effect of Tocilizumab on Serum Hepcidin and Anemia Response in Patients with Rheumatoid Arthritis
Lee, W., & Yoo, W. (2016) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2016.23.2.79
Metadata
- Authors
- Hashizume, M., Uchiyama, Y., Horai, N., Tomosugi, N., & Mihara, M.
- Affiliations
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- Shin Nippon Biomedical Laboratories (Japan) (JP)
- Kanazawa Medical University (JP)
- Corresponding author
- Mihara, Masahiko
- Venue
- Rheumatology International
- Published
- 2009-07-29
- Volume
- 30
- Issue
- 7
- Pages
- 917-923
- ISSN
- 0172-8172 (ISSN-L)
- 1437-160X
- OpenAlex
- W1991338957
- Cited by
- 70
- References
- 27
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 8 · 2015: 1 · 2014: 5 · 2013: 8 · 2012: 5
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Rheumatology International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- tocilizumab, IL-6 receptor inhibition, anemia, collagen-induced arthritis, hepcidin, iron deficiency, IL-6 signaling, C-reactive protein, anti-IL-6 receptor antibody
- MeSH terms
- Interleukin-6 Inhibitors, Anemia, Animals, Antibodies, Monoclonal, Arthritis, Experimental, C-Reactive Protein, Cattle, Collagen, Disease Models, Animal, Female, Gene Expression Regulation, Humans, Injections, Intravenous, Macaca fascicularis, Recombinant Fusion Proteins, RNA, Messenger, Down-Regulation, Interleukin-6, Treatment Outcome, Receptors, Interleukin-6, Antimicrobial Cationic Peptides, Antibodies, Monoclonal, Humanized, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.